Abiopharma

🔍 WENDER JOSEPH H (Director)

Company: IONIS PHARMACEUTICALS INC (IONS)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Sold 11,200 shares of Common Stock at $55.0386 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 125,635.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,600 shares of Common Stock at $57.5311 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,035.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 11,200 shares of Common Stock at $60.1383 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 108,835.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.000 to $55.180 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.500 to $57.575 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.53 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.